首页> Cancer medicine> Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Franziska K,Krebs

第一单位： Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.;German Cancer Consortium (DKTK), Partner Site Mainz/Frankfurt am Main, Mainz, Germany.

作者： Franziska K,Krebs ^[1] ; Emily R,Trzeciak ^[2] ; Sophia,Zimmer ^[2] ; Deniz,Özistanbullu ^[3] ; Heidrun,Mitzel-Rink ^[2] ; Markus,Meissner ^[3] ; Stephan,Grabbe ^[2] ; Carmen,Loquai ^[2] ; Andrea,Tuettenberg ^[1]

作者单位： Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.;German Cancer Consortium (DKTK), Partner Site Mainz/Frankfurt am Main, Mainz, Germany. ^[1] Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. ^[2] Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe University, Frankfurt, Germany. ^[3]

关键词 checkpoint inhibitor immunotherapy malignant melanoma myeloid-derived suppressor cells platelets